Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Specificity, frequency, and phenotype of citrullinated-specific T cells vary with disease activity in rheumatoid arthritis
Cliff Rims, Hannah A. DeBerg, Sylvia E. Posso, Virginia S. Muir, Hannes Uchtenhagen, Anne M. Hocking, Heather Bukiri, Jeffrey Carlin, Bernard Ng, Peter S. Linsley, Eddie A. James, Jane H. Buckner
Cliff Rims, Hannah A. DeBerg, Sylvia E. Posso, Virginia S. Muir, Hannes Uchtenhagen, Anne M. Hocking, Heather Bukiri, Jeffrey Carlin, Bernard Ng, Peter S. Linsley, Eddie A. James, Jane H. Buckner
View: Text | PDF
Research Article Immunology

Specificity, frequency, and phenotype of citrullinated-specific T cells vary with disease activity in rheumatoid arthritis

  • Text
  • PDF
Abstract

In rheumatoid arthritis (RA), CD4+ T cells specific for citrullinated antigens (cit-antigens) are key drivers of disease, but knowledge about epitopes and phenotypes remains limited. We characterized the frequency and phenotype of cit-specific CD4+ T cells in peripheral blood using HLA class II tetramers combined with computational analysis of phenotypic clusters to simultaneously detect peptides derived from 5 cit-antigens (aggrecan, vimentin, fibrinogen, cartilage intermediate layer protein, and α-enolase) previously implicated in RA pathogenesis. In a cross-sectional cohort, cit-aggrecan–, cit-vimentin–, and cit-fibrinogen–specific T cells were more frequent in participants with RA than healthy volunteers, associated with active disease, and had Th1-like and stem-like lineages in RA. In a longitudinal cohort investigating response to therapy, the frequency of cit-aggrecan–, cit-vimentin–, and cit-fibrinogen–specific CD4+ T cells was significantly higher at baseline and further elevated in responders. Furthermore, the frequency of cit-specific Th1-like cells in responders decreased over time. In contrast, the frequency of Th1-like cells in non-responders increased over time. Collectively, these findings demonstrate that cit-specific CD4+ T cells are expanded in RA and target a broad number of antigens across a breadth of phenotypes. Furthermore, the predominant antigen specificities associate with disease activity and exhibit dynamic changes in phenotype that reflect response to therapy.

Authors

Cliff Rims, Hannah A. DeBerg, Sylvia E. Posso, Virginia S. Muir, Hannes Uchtenhagen, Anne M. Hocking, Heather Bukiri, Jeffrey Carlin, Bernard Ng, Peter S. Linsley, Eddie A. James, Jane H. Buckner

×

Figure 1

Cit-specific CD4+ T cells are increased in RA and exhibit antigenic focus in active disease.

Options: View larger image (or click on image) Download as PowerPoint
Cit-specific CD4+ T cells are increased in RA and exhibit antigenic focu...
Ex vivo frequencies of non-naive T cells for (A) combined cit-antigens (P = 0.0148), (B) influenza antigen, and (C) cit-antigens individually (aggrecan P = 0.0004; VimFib P = 0.0078). For A–C, frequency (y-axis) was log2(x + 1) transformed; symbols represent individual participants (HC n = 27, RA n = 64) and horizontal bars show the median. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 by 2-tailed non-parametric Wilcoxon test. (D) Stacked bar plot where each column is an RA participant (N = 61) showing the proportion of each non-naive antigen frequency. The participants were grouped based on individual antigen dominance, where a z score was calculated for each antigen within each individual participant. A dominant antigen was defined as a z score of 1.0 or greater and those participants defined as “none” were undefined due to an all-antigens z score of less than 1.0; numbers within groups are participant counts. Note that 3 RA participants are not shown, as their non-naive frequencies were zero or total event counts were less than 8. (E) Bar graph summarizing the number RA participants with high or low disease activity (wRAPID3 < 2.0 are considered “low” and wRAPID3 > 2.0 are considered “active”) for individuals in each dominant antigen group (as depicted in D). Note that 2 of the participants shown in D did not have reportable wRAPID3 at time of draw; **P ≤ 0.01 by 2-way Fisher’s exact test against those participants grouped as “none.”

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts